AllerGene AI Therapeutics

Executive Summary

AllerGene AI Therapeutics is a Boston-based biotechnology company pioneering a novel in vivo cell and gene therapy approach for severe allergic diseases. Founded in 2020, the company leverages mRNA delivered via lipid nanoparticles (LNPs) to transiently program patients' own immune cells to eliminate mast cells, the root cause of allergic reactions. This strategy aims to reset the immune system without permanent genetic alteration, offering a potential paradigm shift from chronic symptom management to a durable, possibly curative treatment for conditions such as food allergies, asthma, and anaphylaxis. By targeting mast cells directly, AllerGene's platform could address a broad spectrum of IgE-mediated allergies, a market with high unmet need. The company's proprietary LNP formulation enables specific delivery to mast cells, while the mRNA payload encodes a protein that induces temporary cell death. This non-viral, non-integrating approach mitigates long-term safety risks and allows for repeat dosing if necessary. With a strong scientific foundation and a clear translational strategy, AllerGene is positioned to advance its lead candidate into preclinical studies and eventually clinical trials.

Upcoming Catalysts (preview)

• Q3 2027Lead IND filing for first allergic disease indication40% success
• Q4 2026Initial in vivo proof-of-concept data in large animal models70% success
• Q2 2027Series A financing to support IND-enabling studies50% success